Ozempic vs Zepbound

Ozempic (semaglutide by Novo Nordisk) is a once-weekly injection approved for type 2 diabetes, reducing cardiovascular risk, and chronic kidney disease. Zepbound (tirzepatide by Eli Lilly) is also a once-weekly injection but is approved for obesity and obstructive sleep apnea. The main difference is their active ingredients—semaglutide vs. tirzepatide—and their approved uses, with Ozempic targeting diabetes-related conditions and Zepbound focusing on weight management and sleep apnea.

AI summary of the sources below.